100763
论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
Authors Zhao Z, Song ZJ, Wang XW, Sun HF, Yang XM, Yuan Y, Yu P
Received 6 March 2017
Accepted for publication 13 June 2017
Published 21 August 2017 Volume 2017:10 Pages 4129—4133
DOI http://doi.org/10.2147/OTT.S136297
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr Tohru Yamada
Abstract: ROS1 fusion is a common
genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic
lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases
with ROS1 trans. We report the
response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant,
which was different from the two common SLC34A2-ROS1 fusion
types reported in the literature. After crizotinib administration, overall
recovery was good in this patient; the primary lesion was successfully treated,
the lymph node metastases had disappeared, and the metabolism was normal.
Keywords: SLC34A2-ROS1 fusion,
crizotinib, lung adenocarcinoma, next-generation sequencing
摘要视频链接：Crizotinib treatment in lung
adenocarcinoma patient with ROS1 fusion
